Answers are grounded in this paper and cite their sources.
Formulation of niosomes improved sustained release of mefenamic acid in inflammatory conditions, suggesting enhanced bioavailability.
The objective of the present investigation was to develop niosomal based delivery system for application of mefenamic acid for treatment of inflammatory condition. The idea was to increase the bioavailability of drugs. Niosomes are known to present a solution to these side effects and the study proved that niosomes of mefenamic acid can provide improved drug bioavailability via sustained release of the drug. Among various formulations, CF7 was found to have a good release pattern and controlled release up to 24 hrs it could be suggested that the developed Pluronic P85 modified mefenamic acid niosomes could act as constant released niosomal carrier.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: